{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:24:51Z","timestamp":1791811491364,"version":"4.3.4"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chordoma is a rare malignant tumor originating in the notochord characterized by slow progression but frequent recurrences. Systemic treatment for this condition is not well defined. This study aimed to describe real-world clinical practice patterns of systemic therapy and its outcomes in patients with advanced chordoma treated at a sarcoma referral center member of the European Reference Network on Rare Adult Solid Cancers (EURACAN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Consecutive adult patients with histologically confirmed chordoma, diagnosed between 2005 and 2024, who received tyrosine kinase inhibitors (TKI) or immune checkpoint inhibitors (ICI), were retrospectively reviewed. Demographic, clinicopathological, and treatment data were collected from institutional databases. Responses were radiologically assessed according to RECIST criteria by sarcoma radiologists as part of routine clinical care. Data were collected up to December 31, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 13 patients (median age 62 years) were identified. All had undergone surgery, and more than half received adjuvant radiation therapy. Most patients (n=10, 76.9%) received systemic therapy with imatinib as first-line treatment, while a minority (n=2, 15.4%) received ICIs as first-line therapy. Several patients received multiple lines of treatment, including sequential exposure to TKI and ICI. Objective responses were observed in 2 of 5 patients in the TKI-only subgroup (40.0%) and 4 of 8 patients in the ICI-exposed subgroup (50.0%), all of which were partial responses, with prolonged disease stabilization being the a common outcome. The median progression-free survival (PFS) for the entire cohort was 12.3 months, and the median overall survival (OS) was 149.8 months. The median PFS and median OS in the TKI-only subgroup were 7.4 and 113.5 months, respectively, whereas they were 12.7 and 151.6 months in the ICI-exposed subgroup, respectively. Subgroup results are descriptive, exploratory, and hypothesis-generating due to the small sample size.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results indicate that systemic therapy can provide durable disease control in selected patients with chordoma. TKI are commonly used and may provide good responses while ICIs show potential activity in selected patients but await confirmation in robust clinical trials. These real-world data reinforce the need for prospective, multicenter studies to optimize treatment sequencing and patient selection in this rare malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1755538","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T05:22:33Z","timestamp":1770096153000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy and tyrosine kinase inhibitors in chordoma: a real-world data study from a European Reference Network on Rare Adult Solid Cancers member center"],"prefix":"10.3389","volume":"16","author":[{"given":"Mario","family":"Balsa","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Institut Catal\u00e0 d'Oncologia (ICO)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Torrent","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Institut Catal\u00e0 d\u2019Oncologia (ICO)","place":["L\u2019Hospitalet De Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"Plastic Surgery Department, Hospital Universitari de Bellvitge (HUB)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Plastic Surgery Department, Hospital Universitari de Bellvitge (HUB)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Maria","family":"Vi\u00f1als","sequence":"additional","affiliation":[{"name":"Plastic Surgery Department, Hospital Universitari de Bellvitge (HUB)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Pablos","sequence":"additional","affiliation":[{"name":"Orthopedic Surgery and Traumatology Department, Hospital Universitari de Bellvitge (HUB)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fontalva","sequence":"additional","affiliation":[{"name":"Orthopedic Surgery and Traumatology Department, Hospital Universitari de Bellvitge (HUB)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Portabella","sequence":"additional","affiliation":[{"name":"Orthopedic Surgery and Traumatology Department, Hospital Universitari de Bellvitge (HUB)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Lozano","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Institut Catal\u00e0 d\u2019Oncologia (ICO)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gonz\u00e1lez-Viguera","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Institut Catal\u00e0 d\u2019Oncologia (ICO)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Narv\u00e1ez","sequence":"additional","affiliation":[{"name":"Radiology Department, Hospital Universitari de Bellvitge (HUB)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Radiology Department, Hospital Universitari de Bellvitge (HUB)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Sardi\u00f1as","sequence":"additional","affiliation":[{"name":"Radiology Department, Hospital Universitari de Bellvitge (HUB)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Sanjuan","sequence":"additional","affiliation":[{"name":"Pathology Department, Hospital Universitari de Bellvitge (HUB)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Ippoliti","sequence":"additional","affiliation":[{"name":"Pathology Department, Hospital Universitari de Bellvitge (HUB)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma Rosa","family":"Comabella","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Catal\u00e0 d'Oncologia (ICO)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ros\u00f3","family":"Sala","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Catal\u00e0 d'Oncologia (ICO)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Garc\u00eda del Muro","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Catal\u00e0 d'Oncologia (ICO)","place":["L\u2019Hospitalet de Llobregat, Spain"]},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Catal\u00e0 d'Oncologia (ICO)","place":["L\u2019Hospitalet de Llobregat, Spain"]},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Martin-Liberal","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Catal\u00e0 d'Oncologia (ICO)","place":["L\u2019Hospitalet de Llobregat, Spain"]},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL)","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.spinee.2020.10.009","article-title":"Chordoma of the sacrum and mobile spine: a narrative review","volume":"21","author":"Pennington","year":"2021","journal-title":"Spine J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70337-0","article-title":"Chordoma: current concepts, management, and future directions","volume":"13","author":"Walcott","year":"2012","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28032","article-title":"Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population","volume":"119","author":"Smoll","year":"2013","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"102527","DOI":"10.1016\/j.canep.2024.102527","article-title":"Incidence and centralization of chordoma in the Netherlands: A nationwide study between 1991 and 2020","volume":"89","author":"Lipplaa","year":"2024","journal-title":"Cancer Epidemiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2020-0258-RA","article-title":"Chordoma","volume":"146","author":"Ulici","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-11-1344","article-title":"Chordoma: the nonsarcoma primary bone tumor","volume":"12","author":"Chugh","year":"2007","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou331","article-title":"Clinical features and prognostic factors of patients with chordoma in the spine: a retrospective analysis of 153 patients in a single center","volume":"17","author":"Meng","year":"2015","journal-title":"Neuro Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28606","article-title":"High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results","volume":"120","author":"Uhl","year":"2014","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.06.048","article-title":"Effect of carbon ion radiotherapy for sacral chordoma: results of Phase I-II and Phase II clinical trials","volume":"77","author":"Imai","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.3656","article-title":"Phase II study of imatinib in advanced chordoma","volume":"30","author":"Stacchiotti","year":"2012","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.038","article-title":"Imatinib in advanced chordoma: A retrospective case series analysis","volume":"51","author":"Hindi","year":"2015","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv300","article-title":"Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF\/GETO)","volume":"26","author":"Bompas","year":"2015","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1338235","article-title":"First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies","volume":"6","author":"Migliorini","year":"2017","journal-title":"Oncoimmunology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.565945","article-title":"Response of metastatic chordoma to the immune checkpoint inhibitor pembrolizumab: A case report","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2024.1375567","article-title":"Role of immunotherapy in treatment refractory chordomas: review of current evidence","volume":"11","author":"Alexander","year":"2024","journal-title":"Front Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.109721","article-title":"Cracking chordoma\u2019s conundrum: immune checkpoints provide a potential modality","volume":"22","author":"Liu","year":"2025","journal-title":"Int J Med Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"105051","DOI":"10.1016\/j.esmoop.2025.105051","article-title":"First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced Malignancies","volume":"10","author":"Janku","year":"2025","journal-title":"ESMO Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000529503","article-title":"Case report of adAPT-001-mediated sensitization to a previously failed checkpoint inhibitor in a metastatic chordoma patient","volume":"16","author":"Kesari","year":"2023","journal-title":"Case Rep Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1755538\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T05:22:34Z","timestamp":1770096154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1755538\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":18,"alternative-id":["10.3389\/fonc.2026.1755538"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1755538","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"article-number":"1755538"}}